[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus].
OBJECTIVE
Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg.


METHODS
26 patients with type 2 diabetes mellitus and painful neuropathy were included into the study. The duration of pain symptoms ranged from 1 to 3.5 years (mean 1.9 +/- 0.6 year). Pain intensity was assessed using Short-Form McGill Pain Questionnaire (SFMPQ), visual analogue scale (VAS), and Present Pain Intensity Scale (PPI) before the study and after 6-week treatment with gabapentin. The sensory and motor conduction studies, electromyography from tibial anterior muscle and skin sympathetic response were recorded in the patients and compared with the results obtained from the control group.


RESULTS
The neurophysiological examinations carried out in the patients with sensory neuropathy demonstrated a significant conduction impairment in sensory and motor nerves as well as in sympathetic sweat-secreting nerves. After six weeks of gabapentin treatment in 2400 mg daily dose a significant pain reduction was observed, assessed by means of SF-MPQ, VAS and PPI questionnaires. The authors have demonstrated a significant analgesic effect of gabapentin in patients with diabetic neuropathy and the suggest administration of this preparation in chronic diabetic neuropathy in order to improve the quality of patients' life.
Katedra i Klinika Neurologii Akademii Medycznej we Wrocławiu.
Bogusław
B
Paradowski
Małgorzata
M
Bilinska
D000085:Acetates / Q000627:therapeutic use*; D000368:Aged; D000588:Amines; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003929:Diabetic Neuropathies / Q000150:complications*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology*; D011795:Surveys and Questionnaires; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D002121:Calcium Channel Blockers; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin